anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In addition to the general precautions previously described, moderate decreases in blood pressure occur frequently with intra-arterial (brachial) injections. This change is usually transient and requires no treatment; however, the blood pressure should be monitored for approximately ten minutes following injection. Special care is required when venography is performed in patients with suspected thrombosis, phlebitis, severe ischemic disease, local infection or a totally obstructed venous system. In the presence of venous stasis, vein irrigation with normal saline should be considered following the procedure. Venography is optimally performed with a more dilute solution such as Conray 43 (Iothalamate Meglumine Injection USP 43%). 

Extreme caution during injection of the contrast agent is necessary to avoid extravasation and fluoroscopy is recommended. This is especially important in patients with severe arterial or venous disease.
PURPOSE:To obtain the agents, comprising an extract of Echinodorus Macrophyllus Micaeli, a plant known to be effective against arthritis, gout, depuration, renopathy, rheumatism, etc., in the South American district from old times, in an organic solvent or water as an active ingredient. CONSTITUTION:A leaf part of Echinodorus Macrophyllus Micaeli is used in a raw state as it is or dried and ground and then extracted with an organic solvent, water (including hot water) or optionally a mixed solvent of the organic solvent and water and the prepared extract is used as an active ingredient to give an agent having eliminating action on active oxygen, an agent for alleviating hyperlipemia, an agent having antiallergic action and an agent having inhibitory action on aldose reductase. Among the components of the extract, a component having extremely eliminating action on active oxygen is a water-soluble acidic compound. A component having extremely alleviating action on hyperlipemia is an extract with acetone and an extract with hot water. A component having extremely antiallergic action is a component insoluble in 66% methanol among extracts with hot water. A component having extremely suppressing action on aldose reductase is a component having highest fat solubility among extracts with acetone.
Fully accommodative esotropia will be defined as an esotropia which is controlled for distance and near with full hypermetropic correction. Partially accommodative esotropia will be defined as a reduction in the angle of esotropia of 10 dioptres or more for distance or near, using the full hypermetropic correctionAccommodative esotropia with convergence excess occurs when the near angle exceeded the distance angle by 15 dioptres or more when fixating an accommodative target, using the full hypermetropic correction.
We present a case of a 72-year-old liver transplant recipient 7 years prior who presents to our hospital with general malaise, fatigue, low-grade fevers, and watery diarrhea. He was found to have Astrovirus via PCR testing in a comprehensive stool panel. The patient's home mycophenolic acid was held upon admission, while cyclosporine was continued through his hospital stay. Generally, Astroviridae infection is a rarely identified cause of enteritis and even less so in the transplant population. Although reports have been published regarding devastating cases of encephalitis in immunocompromised patients, our patient did not exhibit these symptoms and draws into question the danger of this virus in other immunosuppressed populations. This case helps to better elucidate which patient populations should be approached with caution in the setting of Astroviridae infection.
Three high-volume Italian centers will enroll 195 obese patients who are candidates for metabolic surgery for obesity. Part of them will be established a training cohort (total = 105 patients), used to set up the AI-based method of TSBL measurement. The other 90 patients (30 for each center) will represent the validation cohort.
Prod. (I) is obtd. in bacteria by transformation of a temp.-sensitive bacterial strain carrying a temp.-sensitive phage repressor gene and a functional phage lysozyme-encoding genes. The latter genes are repressed under permissive conditions and expressed under restrictive conditions. - Transformation is with a DNA molecule(s) expressing (I) directly or indirectly. The transformed strain is cultured under permissive conditions such that (I) is formed. Then the temp. is raised to produce restrictive conditions. (I) may be recovered from the culture medium or its concentrate. - DNA fragment comprising a defective phage sequence having a temp. sensitive repressor gene and functional lysozyme encoding genes such that these genes are repressed under permissive conditions and expressed under restrictive conditions, and a selectable marker is new. Bacterium comprising a DNA fragment as defined in paragraph (2) above is new. The bacterium is lytic after transformation with the fragment.
A method relates to medicine, namely to a method for the surgical rehabilitation of the distal divisions of the bowel in the children that are defunctioned for a long time comprises two-week preoperative preparation including anticholinesterase drugs at the age-related doses in combination with colon hydroprocedures with cleansing enemas with 2 % hypertonic solution of sodium chloride. The energy deficiencies are corrected with L-carnitine, coenzyme Q10, riboflavin, thiamine. Then laparotomy is preformed with exploration of the defunctioned bowel divisions. The unloading anastomosis in fashioned in T shape with exteriorization of the afferent loop onto the anterior abdominal wall. In three weeks after the healing of anastomosis, the electrostimulation of bowel is provided. The hypertonic enema is given every day. The fistula is obturated once a day until the abdominal pain syndrome, the non-assisted bowel evacuation, pain disappearance, the satisfactory colonic evacuation in irirgography. Then the natural passage along the bowel is restored by the resection of the distal part of T-shaped anastomosis.
PURPOSE OF REVIEW: Pain is a complex phenomenon that affects millions of individuals worldwide and poses a significant burden on public health. While pain management typically focuses on pharmacological and physical interventions, emerging research suggests that nutrition plays a crucial role in pain modulation. This narrative review aims to explore the relationship between nutrition and pain, providing a comprehensive overview of recent literature. The review covers various dietary factors, including macronutrients, micronutrients, dietary patterns, and specific dietary interventions. Additionally, the potential mechanisms underlying the impact of nutrition on pain are discussed. The findings highlight the potential for dietary interventions to complement traditional pain management approaches and provide valuable insights for future research and clinical practice.
RECENT FINDINGS: Literature suggested the impact of healthy nutrition on improvement in pain and that certain types of food may increase and worsen different pain conditions. Nutrition plays an important role in modulating pain. It is important to counsel patients in pain on best diet for their pain condition to alleviate pain. Our article summarizes very well the issue of nutrition and pain and provides a guide to all practitioners caring for patients with chronic pain.
A depilatory for removing human hair comprises 1 to 6 parts of strontium sulphide mixed with 99 to 94 parts of calcium carbonate. In place of calcium carbonate there may be used the same proportions of strontium carbonate, powdered quartz, lithopone, barium sulphate, stannic acid or aluminium hydroxide. Other filling substances, e.g. starch, may be added.  Comparisons are made between the time of depilation when using the above mixtures and when using mixtures of strontium sulphide with gypsum, talc, titanic acid, magnesium carbonate, magnesium oxide, kieselguhr, calcium hydroxide and zinc oxide.  Specification 18029/89, [Class 1], is referred to
The mother's voice recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group were explored maternal voice, which start from 3 minutes before the procedure, once a day and for three consecutive days.And then recorded the process by the camera, uploaded to YouTube within 24 hours and sent to their mother.
This study aimed to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients. This prospective, single-blinded study included patients hospitalised for influenza infection aged 1 year to 18 years, at MacKay Children's Hospital, Taiwan, between December 2017 and December 2019. The primary outcomes were respiratory symptom severity and the signs that presented within hospitalisation. The durations of fever and hospital stay were also documented. The secondary outcome measures were serial changes in the virus titres, as detected by real-time polymerase chain reaction. Totally 54 patients were enrolled (28 in the control group and 26 in the combination group). There were no differences in the patients' baseline characteristics between the groups. The time to defervescence was significantly shorter in the combination group than the oseltamivir group (13.2 hours vs 32.1 hours, p=0.002). The decrease in the virus titre was more pronounced from days 1 to 3 (log Δ13) in the combination group than the oseltamivir group.(log Δ13: 39% vs 19%, p=0.001). In paediatric settings, combination therapy may be used selectively among patients with a history of febrile convulsion or families anxious about the discomforts associated with the fever itself.
PURPOSE:To obtain a new flavanone glycoside from Matteuccia orientalis (Hook) Trev. or a homologous/analogous plant thereof, having a remarkable inhibitory activity against aldose reductase, thus useful for e.g. treating diabetic complications as an aldose reductase inhibitor having few side effects such as neurotoxicity. CONSTITUTION:This new flavanone glycoside of the formula (R1 is H or methoxy) has a remarkable inhibitory activity against aldose reductase, thus is useful as e.g. a medicine for diabetic complications such as peripheral nerve disorders, cataract, retinopathy, keratopathy and nephropathy. The compound is obtained by the following process: the rhizome of Matteuccia orientalis (Hook) Trev. or a homologous/analogous plant thereof is finely crushed and extracted with chloroform, methanol, and water in order to obtain respectively a chloroform extract, methanol extract and water extract; the methanol extract is then subjected to a Yatrobeads(R) column chromatography and eluted by increasing the polarity of developing solvents using a methanol-chloroform-based solvent, and the resultant active fraction is, in turn, subjected to high-performance liquid chromatography to effect purification.
Candida infection is strongly suspected based on clinical symptoms and the participant's clinical course, white moss (plaque) is observed on the esophageal mucosa, and therapy via intravenous infusion is judged to be suitable for the present episode of esophageal candidiasis. MK-0991 therapy as a single loading dose of 70 mg/m\^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m\^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 7 and 28 days, respectively.
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has evolved as a breakthrough therapy for patients with severe aortic valve stenosis. While TAVR has revolutionized the management of aortic valve disease, the procedure may be associated with the development of conduction disturbances requiring permanent pacemaker implantation. Traditionally, conventional transvenous pacemakers have been used to address these complications. However, the introduction of leadless pacemaker technology, such as the MICRA Transcatheter Pacing System (TPS), offers a novel alternative.
MATERIALS AND METHODS: This was a retrospective single-center study where all patients who underwent TAVR at our center and subsequently required permanent pacemaker implantation within 30 days were reviewed. We included only the patients who underwent leadless pacemaker placement. We then conducted a retrospective chart review to identify patient and procedural characteristics, procedural details, and relevant clinical outcomes.
RESULTS: A total of 9 patients were identified. All of the patients underwent MICRA AV placement within 30 days post-TAVR by an interventional cardiologist. The average age of the cohort was 79.6 years with an average STS score of 3.7 %. The majority of the patients received balloon-expandable valves (78 %). There were no procedural complications in any of the patients. At an average follow-up of 353 days, capture thresholds and lead impedance remained stable with an average RV pacing of 13 %.
CONCLUSION: This small, retrospective cohort demonstrates that the use of MICRA AV leadless pacemakers is feasible after TAVR and is associated with low periprocedural complications. Leadless pacemakers provide stable pacing thresholds and AV synchrony.
<P>PROBLEM TO BE SOLVED: To provide a particulate having a medicinal function more excellent than that of a colloid made of a noble metal simple substance.  <P>SOLUTION: Each metal complex particulate has a particle diameter of 0.7 to 10 nm, and is substantially made of a metal complex, and, as the whole metal complex particulate, the electric charge is substantially controlled to zero. As the metal complex, a noble metal complex is preferably used. The metal complex in this invention is suitably used for medical use. The metal complex particulate can be produced by preparing an aqueous solution using a metal salt, ligands coordinated at metal ions comprised in the metal salt, a pH regulator and water, and stirring the aqueous solution while being held to a temperature of >0 to 10°C.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate capsules, uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia, bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed (see PRECAUTIONS: Hyperprolactinemic States). In the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma (see PRECAUTIONS: Hyperprolactinemic States)and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When bromocriptine is being used to treat acromegaly, prolactinoma, or Parkinson’s disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine is considered to be medically contraindicated.

The drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the postpartum period, the patient should be observed with caution.
PROBLEM TO BE SOLVED: To provide a composition for treating cancer, such as cancer associated with enzyme phosphatase - tension homolog (PTEN) deficiency, small cell lung cancer, meningioma, head and neck cancer, glioblastoma multiforme, anaplastic astrocytoma, and colorectal cancer.SOLUTION: According to the present invention, there is provided a composition comprising a therapeutically effective amount of a compound of formula (I), or a single isomer, stereoisomer, enantiomer, or a mixture thereof. (in the formula, the groups Y and Z are each independently a substituted aryl group or heteroaryl group H, alkenyl, alkoxy, alkyl, etc.; Rto Rare each independently H, halogen, alkenyl, alkoxy, etc.; A and B are each independently H, halogen, alkyl, OH, etc.; Rand Rare each independently H, alkyl, cycloalkyl etc.)SELECTED DRAWING: Figure 1
Investigators will apply the KCCQ to maintenance dialysis patients and statistically analyze baseline KCCQ scores and changing trends to investigate whether they are associated with the occurrence of long-term cardiovascular events and all-cause mortality in dialysis patients and to construct a predictive model associated with KCCQ scores. Patients who meet the inclusion and exclusion criteria will sign an informed consent form, and the baseline index test and the KCCQ assessment will be performed within one week after enrollment. Then the follow-up will be conducted according to the follow-up plan (KCCQ scores and test indexes will be collected at 0, 1, 2, 3, 6, 9 and 12 months in patients with new-onset uremia and the patients with maintenance dialysis will be collected at 0, 3, 6, 9 and 12 months). Conduct a KCCQ assessment and collect relevant indicators during each follow-up visit. There is no intervention in the patient's treatment regimen during the study period. All participants enrolled in the study will be followed up for at least 12 months.
Adalimumab 40 milligrams (mg) subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during the double-blind (DB) period. The dosing frequency of adalimumab was adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (less than \[\<\] 20% improvement from baseline in tender joint count \[TJC\] and swollen joint count \[SJC\] for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in open label extension (OLE) period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
This Special Issue of Genes, titled "Genetic and Molecular Basis of Inherited Disorders", presents a collection of pioneering research articles that advance our understanding of the genetic mechanisms underlying various hereditary diseases. The studies employ cutting-edge genomic techniques, including next-generation sequencing and genome-wide association studies, to elucidate novel genetic variants and their functional implications. Key investigations span a diverse range of conditions, from congenital idiopathic nystagmus and hereditary hearing loss to familial hypercholesterolemia and rare cancer predisposition syndromes. Notable findings include the identification of new gene-disease associations in congenital anomalies of the kidney and urinary tract, the discovery of large genomic rearrangements in breast cancer susceptibility, and insights into the genetic basis of pigmentary traits and associated disease risks. This Special Issue also highlights the significance of copy number variations and rare structural variants in disease pathogenesis. Collectively, these studies underscore the complexity of genetic variation in inherited disorders and demonstrate the critical role of integrating advanced genetic analyses with clinical practice to enhance diagnostic precision and develop targeted therapeutic approaches.
<P>PROBLEM TO BE SOLVED: To obtain a cosmetic that excellently removes stains, wrinkles and drabness, produces a bleaching action and has an excellent handleability.  <P>SOLUTION: The cosmetic is obtained by mixing 100-160 volume parts of honey, 5-14 volume parts of pollen prepared by steaming and then mashing and 0.5-3 volume parts of powdered rose red and allowing the mixture to stand for 2-10 days. The honey and the pollen obtained from plants growing in a highland are preferably used. The use of the cosmetic excellently removes stains, wrinkles and drabness and produces a bleaching action. The cosmetic is preserved at a normal temperature and has an excellent handleability.  <P>COPYRIGHT: (C)2008,JPO&INPIT
After the subjects signed the informed consent, they entered the screening period (D-28 to D-1) for corresponding examination. Participants who were successfully screened were examined at baseline (D-3 to D-1) to re-verify the inclusion criteria. After re-verification of successful screening subjects, they were enrolled in 1:1 parallel groups according to the research center: experimental group treated with amino acid (15) peritoneal dialysate; Control group - glucose peritoneal dialysate treatment. Subjects were randomly enrolled and given the experimental drug from the next morning according to the randomized results. Subjects in the experimental group were treated with 1 bag of amino acid (15) peritoneal dialysate (2L) once a day in the morning, and were subsequently treated with conventional glucose peritoneal dialysate (lactate). Control subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysis solution (lactate) (2L) once. The number of peritoneal dialysate exchange, the amount of fluid exchange and the duration of abdominal retention were adjusted by the researchers according to the specific conditions of the patients. Efficacy and safety were observed during the treatment period (D1-D90). Blood routine and blood biochemistry were monitored for 30 days, 60 days and 90 days of treatment. nPNA, AMC, MAMC, SGA, BMI, Kt/V, etc. are monitored only at 90 days. The total daily ultrafiltration volume of the patients (the experimental group also recorded the ultrafiltration volume of amino acid peritoneal fluid), and all adverse events (aes) and serious adverse events (SAEs) were recorded in detail.
This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.